CA-125/CEA ratio as a prognostic factor in type II endometrial cancer: a single institute experience WCRJ 2022; 9: e2453
DOI: 10.32113/wcrj_202212_2453

  Topic: Gynaecological cancer     Category: Original article

Karadağ İ. Department of Medical Oncology, Çorum Hittite University Erol Olçok Education and Research Hospital, Çorum, Turkey
ikaradag58@gmail.com , Karakaya S. Medical Oncology, Health Science University, Atatürk Chest Diseases and Chest Surgery Education and Research Hospital, Ankara, Turkey , Ateş Ö. Department of Medical Oncology, Dr. A.Y. Oncology Education and Research Hospital, Ankara, Turkey , Çakmak Öksüzoğlu Ö. B. Department of Medical Oncology, Dr. A.Y. Oncology Education and Research Hospital, Ankara, Turkey Abstract Objective: Type II (non-endometrioid) endometrial cancer is less common with an incidence of 10%-20%. It has an aggressive clinical course with heterogeneous clinic pathological features. The aim of this study is to evaluate prognostic factors and survival outcomes in type II endometrial cancer.

Patients and Methods: Patients aged over 18 years with diagnosis of Stage IA-IVB type II endometrial cancer were included to the study. Between 2013 and 2019, a total of 76 patients were evaluated retrospectively.

Results: Median overall survival (OS) was 25 months while median disease-free survival (DFS) was 22 months. Median DFS was 25 months (95% CI: 14.71-35.28) in patients with negative lymph nodes while it was 10 months (95% CI: 6.88-13.11) in patients with positive lymph nodes (p=0.017). Median OS was 28 months (95% CI: 23.05-32.95) in patients with a ratio of CA-125/CEA<25 while it was 16 months (95% CI: 5.19-26.80) in those with a ratio of CA-125/CEA≥25 (p=0.02). Patients with an Eastern Cooperative Oncology Group performance score (ECOG PS) <2 at the time of diagnosis had a significantly longer OS than ECOG PS≥2 [median 29 months (95% CI: 22.99-35.94) vs. 15 months (95% CI: 0.33-29.66); p=0.024]. In multivariate Cox regression analysis CA-125/CEA (HR:1.70, 95% CI: 1.01-2.83, p=0.042) was independent risk factor for OS.

Conclusions: CA-125/CEA ratio may have prognostic significance in type 2 endometrial cancer, but it needs to be supported by randomized clinical trials.

To cite this article Karadağ İ. Department of Medical Oncology, Çorum Hittite University Erol Olçok Education and Research Hospital, Çorum, Turkey
ikaradag58@gmail.com , Karakaya S. Medical Oncology, Health Science University, Atatürk Chest Diseases and Chest Surgery Education and Research Hospital, Ankara, Turkey , Ateş Ö. Department of Medical Oncology, Dr. A.Y. Oncology Education and Research Hospital, Ankara, Turkey , Çakmak Öksüzoğlu Ö. B. Department of Medical Oncology, Dr. A.Y. Oncology Education and Research Hospital, Ankara, Turkey CA-125/CEA ratio as a prognostic factor in type II endometrial cancer: a single institute experience

WCRJ 2022; 9: e2453
DOI: 10.32113/wcrj_202212_2453

Publication History

Submission date: 10 Oct 2022

Revised on: 03 Nov 2022

Accepted on: 24 Nov 2022

Published online: 07 Dec 2022

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.